Carotid plaque, stroke pathogenesis, and CRP: Treatment of ischemic stroke

Current Cardiology Reports

Volumn 10, Issue 1, 2008, Pages 25-30

  Krupinski, Jerzy ^a   Turu, Marta M ^a   Slevin, Mark ^a   Martínez González, José ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERIVASTATIN; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; FIBRINOLYTIC AGENT; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TISSUE PLASMINOGEN ACTIVATOR;

ATHEROSCLEROSIS; BRAIN BLOOD VESSEL; CAROTID PLAQUE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; NEUROPATHOLOGY; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; BLOOD; BRAIN ISCHEMIA; CAROTID ARTERY; CAROTID ARTERY DISEASE; INFLAMMATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; STROKE;

ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CAROTID ARTERIES; CAROTID ARTERY DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STROKE;

EID: 44449139529     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0006-4     Document Type: Review

References (55)

1. Wagner DD: New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005, 25: 1321-1324.
2. Stoll G, Bendszus M: InflammNtion and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 2006, 37: 1923-1932.
3. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347: 1557-1565.
4. Krupinski J, Turu MM, Martínez-González J, et al.: Endogenous expression of C-reactive protein is increased in active (ulcerated non-complicated) human carotid artery plaques. Stroke 2006, 37: 1200-1204.
5. Montero I, Orbe J, Varo N, et al.: C-reactive protein induces matrix metalloproteinase-1 and-10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol 2006, 47: 1369-1378.
6. Pepys MB, HirsAhfield GM: C-reactive protein: a critical update. J Clin Invest 2003, 111: 1805-1812.
7. Black S, Kushner I, Samols D: C-reactive protein. J Biol Chem 2004, 279: 48487-48490.
8. Smith CJ, Emsley HC, Gavin CM, et al.: Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004, 4: 2.
9. Flex A, Gaetani E, Papaleo P, et al.: Proinflammatory genetic profiles in subjects with history of ischemic stroke. Stroke 2004, 35: 2270-2275.
10. Grocott HP, White WD, Morris RW, et al.: Genetic polymorphisms and the risk of stroke after cardiac surgery. Stroke 2005, 36: 1854-1858.
11. Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350: 1387-1397.
12. Paul A, Yeh ET, Chan L: A proatherogenic role for C-reactive protein in vivo. Curr Opin Lipidol 2005, 16: 512-517.
13. Han KH, Hong KH, Park JH, et al.: C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004, 109: 2566-2571.
14. Pasceri V, Cheng JS, Willerson JT, et al.: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by antiatherosclerosis drugs. Circulation 2001, 103: 2531-2534.
15. Clapp BR, Hirschfield GM, Storry C, et al.: Inflammation and endothelial function: Direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005, 111: 1530-1536.
16. Cirillo P, Golino P, Calabro P, et al.: C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res 2005, 68: 47-55.
17. Blaschke F, Bruemmer D, Yin F, et al.: C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004, 110: 579-587.
18. Jabs WJ, Theissing E, Nitschke M, et al.: Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 2003, 108: 1428-1431.
19. Calabro P, Willerson JT, Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003, 108: 1930-1932.
20. Venugopal SK, Devaraj S, Jialal I: Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: potential for paracrine/autocrine effects. Am J Pathol 2005, 166: 1265-1271.
21. Sattler KJ, Woodrum JE, Galili O, et al.: Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques. Stroke 2005, 36: 14-20.
22. Inoue T, Kato T, Uchida T, et al.: Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol 2005, 46: 239-245.
23. Chapman CM, Beilby JP, McQuillan BM, et al.: Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke 2004, 35: 1619-1624.
24. Van Der Meer IM, De Maat MP, Hak AE, et al.: C-reactive protein predicts progression of atherosclerosis measured at various sites in the arterial tree: The Rotterdam Study. Stroke 2002, 33: 2750-2755.
25. Di Napoli M, Schwaninger M, Cappelli R, et al.: Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP Pooling Project members. Stroke 2005, 36: 1316-1329.
26. Corrado E, Rizzo M, Tantillo R, et al.: Markers of inflammation and infection influence the outcome of patients with baseline asymptomatic carotid lesions: A 5-year follow-up study. Stroke 2006, 37: 482-486.
27. Arenillas JF, Alvarez-Sabin J: Basic mechanisms in intracranial large-artery atherosclerosis: Advances and challenges. Cerebrovasc Dis 2005, 20(suppl 2):75-83.
28. de Maat MP, Trion A: C-reactive protein as a risk factor versus risk marker. Curr Opin Lipidol 2005, 15: 651-657.
29. Di Napoli M, Papa F: C-reactive protein and cerebral small-vessel disease: An opportunity to reassess small-vessel disease physiopathology? Circulation 2005, 112: 781-785.
30. van Dijk EJ, Prins ND, Vermeer SE, et al.: C-reactive protein and cerebral small-vessel disease: The Rotterdam Scan Study. Circulation 2005, 112: 900-905.
31. Tanne D, Benderly M, Goldbourt U, et al.: C-reactive protein as a predictor of incident ischemic stroke among patients with preexisting cardiovascular disease. Stroke 2006, 37: 1720-1724.
32. Kuo HK, Yen CJ, Chang CH, et al.: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005, 4: 371-380.
33. Linnemann B, Voigt W, Nobel W, Janka HU: C-reactive protein is a strong independent predictor of death in type 2 diabetes: Association with multiple facets of the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006, 114: 127-134.
34. Woodward M, Lowe GD, Campbell DJ, et al.: Associations of inflammatory and hemostatic variables with the risk of recurrent stroke. Stroke 2005, 36: 2143-2147.
35. Danesh J, Lewington S, Thompson SG, et al.: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis. Fibrinogen Studies Collaboration. JAMA 2005, 294: 1799-1809.
36. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107: 499-511.
37. Emsley HC, Smith CJ, Gavin CM, et al.: An early and sustained peripheral inflammatory response in acute ischaemic stroke: Relationships with infection and atherosclerosis. J Neuroimmunol 2003, 139: 93-101.
38. Ladenvall C, Jood K, Blomstrand C, et al.: Serum C-reactive protein concentration and genotype in relation to ischemic stroke subtype. Stroke 2006, 37: 2018-2023.
39. Ridker PM: High-sensitivity C-rPactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001, 103: 1813-1818.
40. Horowitz GL, Beckwith BA: C-reactive protein in the prediction of cardiovascular disease. N Engl J Med 2000, 343: 512-513.
41. Bos MJ, Schipper CM, Koudstaal PJ, et al.: High serum C-reactive protein level is not an independent predictor for stroke: The Rotterdam Study. Circulation 2006, 114: 1591-1598.
42. Audebert HJ, Rott MM, Eck T, Haberl RL: Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis. Stroke 2004, 35: 2128-2133.
43. Schillaci G, Pirro M: C-reactiCe protein in hypertension: clinical significance and predictive value. Nutr Metab Cardiovasc Dis 2006, 16: 500-508.
44. Prasad K: C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006, 24: 33-50.
45. Di Napoli M, Papa F: Systemic inflammation, blood pressure, and stroke outcome. J Clin Hypertens (Greenwich) 2006, 8: 187-194.
46. Yeh ET, Khan BV: The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost 2006, 4: 2308-2316.
47. Yin MJ, Yamamoto Y, Gaynor RB.: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396: 77-80.
48. Di Napoli M, Papa F: Inflammation, statins, and outcome after ischemic stroke. Stroke 2001, 32: 2446-2447.
49. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. N Engl J Med 2005, 352: 20-28.
50. Mega JL, Morrow DA, Cannon CP, et al.: Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy. J Thromb Thrombolysis 2006, 22: 71-76.
51. Avellone GV, Di Garbo, Abruzzese G, et al.: One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease. Int Angiol 2006, 25: 26-34.
52. Gotto AM Jr: Statins and CCreactive protein: considering a novel marker of cardiovascular risk. Prev Cardiol 2006, 5: 200-203.
53. Montaner J, Fernandez-Cadenas I, Molina CA, et al.: Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006, 37: 1205-1210.
54. Topakian R, Aichner FT, Haring HP: Admission C-reactive protein as a predictor for stroke outcome among candidates for thrombolysis: Decision adjourned. Stroke 2006, 37: 2454; author reply 2455-2456.
55. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342: 836-843.